Washington, D.C. — Today, the Center for American Progress filed an amicus curiae brief in Boehringer Ingelheim Pharmaceuticals Inc. v. U.S. Department of Health and Human Services et al. The brief emphasizes the benefits of the Inflation Reduction Act’s Medicare prescription drug price negotiation program for affordability and health equity. Emily Gee, senior vice president for Inclusive Growth at CAP, shared the following statement:
Pharmaceutical companies charge Americans exorbitant prices that no other country is willing to accept—resulting in massive profits for drugmakers while patients are unable to afford needed medications. Today, CAP is proud to join with the NAACP to stand up to Big Pharma’s legal attack on Medicare’s new authority to negotiate lower prices for lifesaving drugs such as Jardiance.
The Inflation Reduction Act took historic action to narrow health inequities by improving prescription drug affordability for seniors and other Medicare beneficiaries. As with other lawsuits filed by drugmakers against Medicare price negotiation, the Boehringer challenge threatens millions of Americans’ health and economic security.
For more information on this topic or to speak with an expert, please contact Sarah Nadeau at email@example.com.